Jacobs Levy Equity Management’s Karyopharm Therapeutics KPTI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-18,964
| Closed | -$246K | – | 1000 |
|
|
2023
Q4 | $246K | Sell |
18,964
-137,938
| -88% | -$1.79M | ﹤0.01% | 909 |
|
|
2023
Q3 | $3.15M | Buy |
156,902
+111,778
| +248% | +$2.25M | 0.02% | 469 |
|
|
2023
Q2 | $1.21M | Sell |
45,124
-26,548
| -37% | -$713K | 0.01% | 665 |
|
|
2023
Q1 | $4.18M | Sell |
71,672
-78,288
| -52% | -$4.57M | 0.03% | 441 |
|
|
2022
Q4 | $7.65M | Buy |
149,960
+44,458
| +42% | +$2.27M | 0.05% | 322 |
|
|
2022
Q3 | $8.64M | Buy |
105,502
+3,699
| +4% | +$303K | 0.07% | 284 |
|
|
2022
Q2 | $6.89M | Buy |
101,803
+57,569
| +130% | +$3.89M | 0.05% | 357 |
|
|
2022
Q1 | $4.89M | Buy |
+44,234
| New | +$4.89M | 0.03% | 431 |
|
|
2021
Q3 | – | Sell |
-5,417
| Closed | -$839K | – | 1087 |
|
|
2021
Q2 | $839K | Buy |
+5,417
| New | +$839K | 0.01% | 775 |
|
|
2021
Q1 | – | Sell |
-2,835
| Closed | -$658K | – | 1072 |
|
|
2020
Q4 | $658K | Buy |
+2,835
| New | +$658K | 0.01% | 815 |
|
|
2020
Q1 | – | Sell |
-8,834
| Closed | -$2.54M | – | 1047 |
|
|
2019
Q4 | $2.54M | Buy |
8,834
+3,981
| +82% | +$1.14M | 0.02% | 500 |
|
|
2019
Q3 | $700K | Buy |
+4,853
| New | +$700K | 0.01% | 668 |
|
|
2019
Q1 | – | Sell |
-1,953
| Closed | -$275K | – | 995 |
|
|
2018
Q4 | $275K | Buy |
1,953
+6
| +0.3% | +$845 | ﹤0.01% | 824 |
|
|
2018
Q3 | $497K | Sell |
1,947
-2,106
| -52% | -$538K | 0.01% | 779 |
|
|
2018
Q2 | $1.03M | Buy |
4,053
+586
| +17% | +$149K | 0.02% | 659 |
|
|
2018
Q1 | $698K | Sell |
3,467
-80
| -2% | -$16.1K | 0.01% | 716 |
|
|
2017
Q4 | $511K | Buy |
3,547
+1,907
| +116% | +$275K | 0.01% | 746 |
|
|
2017
Q3 | $270K | Buy |
1,640
+760
| +86% | +$125K | 0.01% | 808 |
|
|
2017
Q2 | $119K | Sell |
880
-636
| -42% | -$86K | ﹤0.01% | 886 |
|
|
2017
Q1 | $292K | Sell |
1,516
-1,391
| -48% | -$268K | 0.01% | 728 |
|
|
2016
Q4 | $410K | Buy |
2,907
+247
| +9% | +$34.8K | 0.01% | 716 |
|
|
2016
Q3 | $388K | Buy |
2,660
+240
| +10% | +$35K | 0.01% | 756 |
|
|
2016
Q2 | $244K | Buy |
+2,420
| New | +$244K | 0.01% | 954 |
|